Akynzeo is a medication used to prevent nausea and vomiting associated with chemotherapy [1]. It is a combination of netupitant and palonosetron [2].
What is Akynzeo used for?
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy [3]. It is available as a capsule for oral administration [4].
How does Akynzeo work?
Akynzeo combines two active ingredients: netupitant, a selective NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist [2]. Netupitant works by blocking the action of substance P, a chemical in the brain that plays a role in nausea and vomiting. Palonosetron works by blocking the action of serotonin, another chemical involved in triggering nausea and vomiting [3].
What are the active ingredients in Akynzeo?
The active ingredients in Akynzeo are netupitant and palonosetron [2].
How is Akynzeo administered?
Akynzeo is taken orally in capsule form [4]. The recommended dose is one capsule taken approximately one hour before initiating each emetogenic chemotherapy cycle [3].
What are the potential side effects of Akynzeo?
Common side effects reported in clinical trials include headache, fatigue, constipation, and indigestion [3]. Serious side effects are rare but can include allergic reactions [4]. Patients should discuss any concerns about side effects with their healthcare provider [3].
What is the recommended dosage for Akynzeo?
The recommended dosage is one capsule taken orally about one hour before starting chemotherapy [3].
Where can I find more information about Akynzeo?
More detailed patient product information, including prescribing information and safety data, can typically be found on the manufacturer's website or through healthcare providers. Information on drug patents and exclusivity for Akynzeo and related compounds can be found on DrugPatentWatch.com [5].
When does patent exclusivity for Akynzeo expire?
Information regarding patent expiration dates for Akynzeo and its components can be accessed through specialized databases like DrugPatentWatch.com [5]. These dates are crucial for determining when generic or biosimilar versions may become available.
Are there any alternatives to Akynzeo for chemotherapy-induced nausea and vomiting?
Several other medications are available to manage chemotherapy-induced nausea and vomiting, including other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids, often used in combination therapy [3]. The choice of treatment depends on the type and intensity of chemotherapy used and individual patient factors.
Who manufactures Akynzeo?
Akynzeo was developed by Helsinn [1].
What clinical data supports Akynzeo's use?
Clinical trials have demonstrated Akynzeo's efficacy in preventing both acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy [3].
What should patients tell their doctor before taking Akynzeo?
Patients should inform their doctor about all medical conditions, allergies, and any other medications they are taking, including over-the-counter drugs and herbal supplements [4].
Sources:
[1] https://www.helsinn.com/products/akynzeo/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/akynzeo-netupitant-and-palonosetron-capsules-and-akynzeo-iv-netupitant-and-palonosetron-injection
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo
[4] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41988876-d489-4328-91e5-278b77977285
[5] https://drugpatentwatch.com/